2025年全球保健品市场规模突破4300亿元，口服美容、肠胃健康、骨关节营养等细分赛道增速超30%。 社淘电商通过"灵犀洞察"工具锁定高潜力品类： 口服美容：胶原蛋白、谷胱甘肽等成分产品因"内调外养"概念持续走热，某国产品牌通过社淘的数据选 品模型调整配方，转化率提升40%； 肠胃健康：益生菌、膳食纤维产品复购率超50%，社淘协助品牌优化包装设计（如独立小袋装），客单 价提升25%； 合规赋能：针对欧美市场，社淘提供"蓝帽子"认证、FDA备案等合规方案，某中国品牌仅用3个月完成 美国资质审核，规避了50万元罚款风险。 2025年全球跨境电商进入精细化运营阶段，品牌若想从0到1实现破圈，需精准把握细分品类趋势并匹配 专业代运营能力。社淘电商凭借"数据选品+全域营销+合规赋能"三位一体模式，已助力100+品牌实现 跨境增长跃迁。以下是聚焦保健、美妆、食品三大类目的选品策略与实战案例。 一、保健品：功能细分驱动增长 案例：合作品牌"VitaGlow"通过社淘的"成分升级+小红书种草"策略，将胶原蛋白肽产品定位为"熬夜肌 修复神器"，6个月内天猫国际旗舰店GMV突破3000万元。 二、美妆个护：场景化与本土化突围 2 ...

又一香港保健品市场赴港IPO。 7月29日，正品控股有限公司(以下简称：正品控股)向港交所主板递交上市申请，浤博资本有限公司为其 独家保荐人。 招股书显示，正品控股主要在香港从事保健及美容补充品与产品的开发、销售、营销及分销。集团将产 品的生产外包给供货商(包括制造商)并主要通过万宁在香港的零售门市以集团自有品牌及第三方品牌分销 集团的产品。根据弗若斯特沙利文的资料，按2024年保健及美容补充品与产品的零售值计算，集团于香 港所有本地保健及美容补充品与产品供货商中排名第七，市场占有率约为1.6%。 营收增长难掩盈利波动 在本地的保健及美容补充品与产品市场中，集团拥有多样化的产品组合，涵盖各年龄层的男性、女性及 儿童的需求，并专注于鹿相关保健补充品、关节及痛症以及外用止痛产品的利基市场。 根据弗若斯特沙利文的资料，集团于2024年在香港鹿相关保健补充品及产品的零售值排名第一，市场份 额约为29.4%；集团自有品牌"炎痛消"旗下的关节及痛症以及外用止痛产品是2024年万宁零售门市中最畅 销的五种关节及痛症补充品及产品之一。 截至最后实际可行日期，该集团经营合共六个自有品牌，即(a)"正品"；(b)"炎痛消"； ( ...

又一香港保健品市场赴港IPO。 7月29日，正品控股有限公司（以下简称：正品控股）向港交所主板递交上市申请，浤博资本有限公司为 其独家保荐人。 在本地的保健及美容补充品与产品市场中，集团拥有多样化的产品组合，涵盖各年龄层的男性、女性及 儿童的需求，并专注于鹿相关保健补充品、关节及痛症以及外用止痛产品的利基市场。 根据弗若斯特沙利文的资料，集团于2024年在香港鹿相关保健补充品及产品的零售值排名第一，市场份 额约为29.4%；集团自有品牌"炎痛消"旗下的关节及痛症以及外用止痛产品是2024年万宁零售门市中最畅 销的五种关节及痛症补充品及产品之一。 截至最后实际可行日期，该集团经营合共六个自有品牌，即(a)"正品"；(b)"炎痛消"； (c)"Organicpharm"；(d)"日药堂"；(e)"维再生"；及(f)"Profix"；及合共六个第三方品牌，包括(其中包括) (a) "iPro+"；及(b)"Boiron"。 业绩表现来看，截至2025年3月31日止的3个财政年度（以下简称：报告期内，下同）公司实现收益分别 约为0.43亿港元、1.10亿港元、1.3亿港元;同期，年内溢利及全面收益总额分别约为1131 ...

Core Viewpoint - Shanghai Jiaoda Onlly Co., Ltd. reported a decline in key financial metrics for the first half of 2025, indicating challenges in revenue generation and profitability amidst a competitive market environment [1][2]. Financial Performance - The company's operating revenue for the first half of 2025 was CNY 150.77 million, a decrease of 5.77% compared to CNY 160.01 million in the same period last year [2]. - Total profit for the period was CNY 6.99 million, down 19.06% from CNY 8.64 million year-on-year [2]. - Net profit attributable to shareholders was CNY 2.25 million, reflecting a 30.54% decline from CNY 3.24 million in the previous year [2]. - The net cash flow from operating activities was negative at CNY -9.49 million, a significant drop from CNY 21.70 million in the same period last year, marking a 143.71% decrease [2]. - Total assets decreased by 2.89% to CNY 736.93 million from CNY 758.88 million at the end of the previous year [2]. Business Overview - The primary business segments include the research, production, and sales of health products, health food, and health product raw materials, as well as the operation and management of elderly medical care institutions [3][5]. - The health product segment focuses on probiotics and plant extracts, with a diverse product line aimed at various health needs [3]. - The company has established a strong presence in the health industry, which is projected to grow significantly, with the total revenue expected to exceed CNY 9 trillion by 2024 and reach CNY 16 trillion by 2030, reflecting a compound annual growth rate of approximately 12% [3]. Market Position and Strategy - The company emphasizes research and development, having launched new products such as probiotic personal care items and pet nutrition supplements during the reporting period [3][5]. - The health product raw materials business is facing increased competition, prompting the company to optimize its workforce and improve production processes to enhance efficiency [5]. - The elderly care segment operates six self-managed profit-oriented medical care institutions, providing a range of services including medical care, rehabilitation, and daily living support [5][6]. Competitive Advantages - The company possesses a robust platform for probiotics and plant extraction resources, supported by extensive research collaborations with academic institutions [6]. - It has received numerous accolades, enhancing its brand recognition and consumer loyalty in the health product market [6]. - The company maintains a comprehensive quality control system and has achieved various certifications, ensuring product safety and efficacy [6].

登录新浪财经APP 搜索【信披】查看更多考评等级 具体来看，交大昂立报告期内实现营业收入1.51亿元，同比下降5.77%；归属上市公司股东的净利润 224.86万元，同比下降30.54%；扣除非经常性损益后的归属于上市公司股东的净利润为-212.85万元，同 比增亏。 公告显示，目前交大昂立的主要业务为保健品、保健食品和保健品原料的研发、生产、销售，以及老年 医疗护理机构的运营及管理。从去年年报中可知，2024年度交大昂立的保健品业务、房地产业务、医养 业务的营收占比分别为48.45%、5.01%、45.33%。 面对每天上千份上市公司公告该看哪些？重大事项公告动辄几十页几百页重点是啥？公告里 一堆专业术语不知道算利好还是利空？请看智通财经公司新闻部《速读公告》栏目，我们派 驻全国的记者们将于公告当晚为您带来准确、快速、专业的解读。 智通财经7月30日讯（记者 沈娇娇）今日，交大昂立（600530.SH）发布2025半年度报告，其营业收入 和归属上市公司股东的净利润同比双双下降，且公司本月刚刚被中国证监会立案。 值得一提的是，7月11日，交大昂立收到中国证监会《立案告知书》，因涉嫌信息披露违法违规，根据 相关 ...

证券日报网讯 7月30日晚间，寿仙谷发布公告称，近日，公司全资子公司金华寿仙谷药业有限公司 的"寿仙品牌破壁灵芝孢子粉"产品完成了国产保健食品备案工作，并获得浙江省市场监督管理局发放的 国产保健食品备案凭证。 （编辑 任世碧） ...

2024年1至12月份，仙乐健康的营业收入构成为：软胶囊占比47.1%，软糖占比23.63%，片剂占比 7.73%，功能饮品占比5.89%，粉剂占比5.5%，硬胶囊占比5.29%。 仙乐健康（SZ 300791，收盘价：23.46元）7月30日晚间发布公告称，公司第四届第十二次董事会临时 会议于2025年7月30日以通讯会议方式召开。会议审议了《关于不向下修正"仙乐转债"转股价格的议 案》等文件。 （文章来源：每日经济新闻） ...

格隆汇7月30日丨交大昂立（维权）(600530.SH)公布2025年半年度报告，报告期实现营业收入1.51亿 元，同比下降5.77%；归属于上市公司股东的净利润224.86万元，同比下降30.54%；基本每股收益 0.0029元。 ...

广发证券股份有限公司 关于威海百合生物技术股份有限公司差异化权益分派 事项的核查意见 广发证券股份有限公司（以下简称"广发证券"或"保荐人"）作为威海百 合生物技术股份有限公司（以下简称"百合股份"、"上市公司"或"公司"）首 次公开发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《上海证券 交易所股票上市规则》《上海证券交易所上市公司自律监管指引第 7 号—回购股 份》《上海证券交易所上市公司自律监管指南第 2 号—业务办理》等相关法律法 规的要求，对百合股份差异化权益分派事项进行了审慎核查，具体情况如下： 《上海证券交易所 上市公司自律监管指引第 7 号—回购股份》等相关法律法规、规范性文件和《公 司章程》的相关规定，公司已回购股份不参与利润分配。基于以上情况，造成公 司本次权益分派实施时股权登记日的总股本与实际参与分配的股份总数存在差 异。因此，公司 2024 年度利润分配实施差异化分红。 二、股东会审议通过的差异化权益分派的方案及调配现金分红总额 公司于2025年6月6日召开了2024年年度股东大会，审议通过了《关于公司 净利润139,309,114.98元，截 至2024年12 月31日，公司 ...

Core Insights - The health supplement market in China has become one of the largest globally, with significant growth potential remaining in the trillion-yuan market [1] - The online health supplement market is projected to exceed 120 billion by 2025, with an overall growth rate of 15% [2] - The consumer demographic is evolving, with a notable shift towards a "dumbbell-shaped" structure, where older adults and new middle-class consumers are driving demand [10] Market Overview - China's health supplement market is large and growing rapidly, with a projected market size of 399.8 billion in 2024, reflecting a 3% year-on-year growth [1] - By 2030, the market size is expected to surpass 1.5 trillion, maintaining a high compound annual growth rate [1] E-commerce Trends - E-commerce platforms are crucial channels for the health supplement industry, showing heightened growth trends [2] - Interest e-commerce is outpacing traditional shelf e-commerce, achieving over 20% annual growth [2] Product Development - The health supplement efficacy landscape is evolving, with traditional categories like bone health and immunity remaining strong, while new categories like moisture removal and emotional health are emerging [2][4] - Innovative product forms such as micro-bubbles and unique capsules are gaining traction, enhancing consumer experience beyond traditional forms [4] Pricing Dynamics - The average daily price of health supplements is around 10 yuan, with most efficacy products priced below 6 yuan, while categories like weight management and anti-aging command higher prices [6] - New products are achieving a premium price point, with an average daily price of 15.8 yuan compared to 8.7 yuan for older products, indicating a trend towards premiumization [8] New Product Strategy - 58% of existing brands are focusing on new product launches, averaging 4 new SKUs per brand annually, highlighting the importance of innovation in brand strategy [8] - New products account for 54% of the market by quantity, although they currently represent only 24% of sales, indicating growth potential [8] Consumer Demographics - The consumer base is shifting, with older adults (60+) contributing significantly to the market, transitioning from basic health to chronic disease prevention and management [10] - The new middle-class demographic (ages 25-45) is emerging as a core growth driver, shifting their focus from "curing" to "preventing" health issues [10]